« Additional results showed a pronounced difference in the molecular response (JAK2V617F burden) between the 2 treatment arms, with “striking superiority of ropeginterferon at month 60,” Gisslinger noted.
Specifically, the median JAK2V617F allele burden at year 5 was 8.5 in the ropeginterferon arm vs 44.4 in the control arm (P < .0001). Additionally, the percentage of patients with a JAK2V617F burden of less than 10% was 53% vs 12% in the investigative and control arms, respectively (P <.0001).
Approximately 69% of patients assigned to ropeginterferon vs 21.6% of those assigned to the control experienced a molecular response at 5 years according to ELN criteria (P <.0001) »
Thanks for posting. So the trial compariston was the new interferon with hydrea. Then the hydrea group could switch to the new interferon. And the result was no venesections and HCT kept in right range and JAK 2 burden very low or non existant for a high proportion of the group. I wonder what the results would be if the trial was old interferon v new interferon. It is good to see that the trial had such a long time ie 5 years. That too gives hope.
There wouldn’t be a huge difference between the old and new interferon , although one would expect a significantly lower drop-out in the group treated with the new interferon.
I wonder about the efficiency of the new interferon vs old. Because I am on Pegasys for about 12 years. Allele burden is 31/25% depending on the test. That's a long way from remission. So hopefully the new interferon will be significantly different. It is probably easier to get good results from the comparison with Hydrea because this doesn't reduce the Jak2 burden. I just hope the new ropeginterferon is sufficiently different and even more relevant - that we will be able to be prescribed it. Thanks for your postings on important research.
According to JJ Kiladjian you would need to be phlebotomy free for 2 consecutive years with an Allele burden below 10% to be considered in remission. You seem to slowly getting there! 🤞🏻
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Molecular Response vs progression, Rux
